BRAF and cutaneous melanoma: Here, we conducted a sensitive ddPCR analysis to detect and quantify ctDNA in plasma samples prospectively and serially collected from resected BRAF-mutated cutaneous melanoma (CM) patients during targeted therapy with BRAF and MEK inhibitors, or immunotherapy, in adjuvant setting.